The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers
Open accessAbstract
The coronavirus disease 2019 (COVID-19) pandemic has led to dramatic changes in oncology practice. It is currently unknown whether programmed death 1 (PD-1) blockade therapy affects severity of illness from COVID-19 in patients with cancer. To address this uncertainty, we examined consecutive patients with lung cancers who were diagnosed with COVID-19 and examined severity on the basis of no or prior receipt of PD-1 blockade. Overall, the severity of COVID-19 in patients with lung cancer was high, including need for hospitalization in more than half of patients and death in nearly a quarter. Prior PD-1 blockade was, as expected, associated with smoking status. After adjustment for smoking status, PD-1 blockade exposure was not associated with increased risk of severity of COVID-19. PD-1 blockade does not appear to affect the severity of COVID-19 in patients with lung cancers. Significance: A key question in oncology practice amidst the COVID-19 pandemic is whether PD-1 blockade therapy affects COVID-19 severity. Our analysis of patients with lung cancers supports the safety of PD-1 blockade treatment to achieve optimal cancer outcomes. This article is highlighted in the In This Issue feature, p. 1079
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., Li, C., Ai, Q., Lu, W., Liang, H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30096-6 · Cited by 4,384
Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State
Arentz, M., Yim, E., Klaff, L., Lokhandwala, S., Riedo, F. X., Chong, M., & Lee, M. (2020) · JAMA · doi:10.1001/jama.2020.4326 · Cited by 2,259
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
Into the Eye of the Cytokine Storm
Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., & Katze, M. G. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05015-11 · Cited by 1,940
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
Functional exhaustion of antiviral lymphocytes in COVID-19 patients
Zheng, M., Gao, Y., Wang, G., Song, G., Liu, S., Sun, D., Xu, Y., & Tian, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0402-2 · Cited by 1,768
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Self-citationDai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z., Zhang, Z., You, H., Wu, M., Zheng, Q., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0422 · Cited by 1,589
Spread of SARS-CoV-2 in the Icelandic population
Gudbjartsson, D. F., Helgason, A., Jonsson, H., Magnusson, O. T., Melsted, P., Norddahl, G. L., Saemundsdottir, J., Sigurdsson, A., Sulem, P., Agustsdottir, A. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006100 · Cited by 1,248
Peripheral T cell expansion predicts tumour infiltration and clinical response
Wu, T. D., Madireddi, S., de Almeida, P. E., Banchereau, R., Chen, Y.-J. J., Chitre, A. S., Chiang, E. Y., Iftikhar, H., O’Gorman, W. E., Au-Yeung, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2056-8 · Cited by 770
Cited by
Risk factors for severe and critically ill COVID‐19 patients: A review
Gao, Y., Ding, M., Dong, X., Zhang, J., Kursat Azkur, A., Azkur, D., Gan, H., Sun, Y., Fu, W., Li, W., et al. (2021) · Allergy · doi:10.1111/all.14657 · Cited by 1,402
Determinants of COVID-19 disease severity in patients with cancer
Robilotti, E. V., Babady, N. E., Mead, P. A., Rolling, T., Perez-Johnston, R., Bernardes, M., Bogler, Y., Caldararo, M., Figueroa, C. J., Glickman, M. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0979-0 · Cited by 628
Self-citationGrivas, P., Khaki, A. R., Wise-Draper, T. M., French, B., Hennessy, C., Hsu, C.-Y., Shyr, Y., Li, X., Choueiri, T. K., Painter, C. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.024 · Cited by 309
COVID-19 in patients with lung cancer
Luo, J., Rizvi, H., Preeshagul, I. R., Egger, J. V., Hoyos, D., Bandlamudi, C., McCarthy, C. G., Falcon, C. J., Schoenfeld, A. J., Arbour, K. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.007 · Cited by 267
Self-citation
Metadata
- Authors
- Luo, J., Rizvi, H., Egger, J. V., Preeshagul, I. R., Wolchok, J. D., & Hellmann, M. D.
- Venue
- Cancer Discovery
- Published
- 2020-08-01
- Volume
- 10
- Issue
- 8
- Pages
- 1121-1128
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3024048796
- Cited by
- 232
- References
- 11
- FWCI
- 17.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. https://app.cochat.ai/papers/10.1158/2159-8290.cd-20-0596
- The paper
- Luo, J., Rizvi, H., Egger, J. V., Preeshagul, I. R., Wolchok, J. D., & Hellmann, M. D. (2020). Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-0596
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.